Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00219609 · ClinicalTrials.gov registry record · Phase 2
Assessment Of Safety Of UK-390,957
A Phase 2 study of Ejaculation, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,058
- Enrollment target
- 20
- Study locations
NCT00219609 is a Phase 2 study of Ejaculation that has completed, run by Pfizer. The registered enrollment target is 1,058 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT00219609, a Phase 2 study of Ejaculation, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,058 participants
- Enrollment target
- 20
- Study locations
Study Summary
To determine whether UK-390,957 is a safe treatment for premature ejaculation.
Conditions Studied
Interventions
- DRUG UK-390,957
Study Locations (20)
California
- Pfizer Investigational Site - Anaheim
- Pfizer Investigational Site - Atherton
- Pfizer Investigational Site - Beverly Hills
- Pfizer Investigational Site - Laguna Woods
- Pfizer Investigational Site - Newport Beach
- Pfizer Investigational Site - Redwood City
- Pfizer Investigational Site - San Diego
- Pfizer Investigational Site - Tarzana
- Pfizer Investigational Site - Walnut Creek
Indiana
- Pfizer Investigational Site - Evansville
- Pfizer Investigational Site - Fort Wayne
- Pfizer Investigational Site - Indianapolis
Florida
- Pfizer Investigational Site - Aventura
- Pfizer Investigational Site - New Port Richey
Kentucky
- Pfizer Investigational Site - Lexington
- Pfizer Investigational Site - Madisonville
Arizona
- Pfizer Investigational Site - Tucson
Colorado
- Pfizer Investigational Site - Aurora
Connecticut
- Pfizer Investigational Site - Waterbury
Louisiana
- Pfizer Investigational Site - Metairie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,058 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00219609
The ClinicalTrials.gov registry entry for NCT00219609 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,058 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ejaculation appearing as the primary indexed condition, and to 1 intervention - of which UK-390,957 is the first listed.
NCT00219609 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Indiana, Florida.
Frequently Asked Questions
What is clinical trial NCT00219609 about?
NCT00219609 is a clinical study titled "Assessment Of Safety Of UK-390,957". To determine whether UK-390,957 is a safe treatment for premature ejaculation.
What is the current status of trial NCT00219609?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,058 participants. The study started on 2005-01. Estimated completion is 2006-03.
What conditions does trial NCT00219609 study?
This clinical trial studies the following conditions: Ejaculation.
What interventions are being tested in trial NCT00219609?
The interventions under investigation include: UK-390,957 (DRUG).
Who is sponsoring clinical trial NCT00219609?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00219609 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ejaculation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.